BACKGROUND: Targeting tumor metabolism by energy restriction-mimetic agents (ERMAs) has emerged as a strategy for cancer therapy/prevention. Evidence suggests a mechanistic link between ERMA-mediated antitumor effects and epigenetic gene regulation. METHODS: Microarray analysis showed that a novel thiazolidinedione-derived ERMA, CG-12, and glucose deprivation could suppress DNA methyltransferase (DNMT)1 expression and reactivate DNA methylation-silenced tumor suppressor genes in LNCaP prostate cancer cells. Thus, we investigated the effects of a potent CG-12 derivative, CG-5, vis-à-vis 2-deoxyglucose, glucose deprivation and/or 5-aza-deoxycytidine, on DNMT isoform expression (Western blotting, RT-PCR), DNMT1 transcriptional activation (luciferase reporter assay), and expression of genes frequently hypermethylated in prostate cancer (quantitative real-time PCR). Promoter methylation was assessed by pyrosequencing analysis. SiRNA-mediated knockdown and ectopic expression of DNMT1 were used to validate DNMT1 as a target of CG-5. RESULTS: CG-5 and glucose deprivation upregulated the expression of DNA methylation-silenced tumor suppressor genes, including GADD45a, GADD45b, IGFBP3, LAMB3, BASP1, GPX3, and GSTP1, but also downregulated methylated tumor/invasion-promoting genes, including CD44, S100A4, and TACSTD2. In contrast, 5-aza-deoxycytidine induced global reactivation of these genes. CG-5 mediated these epigenetic effects by transcriptional repression of DNMT1, which was associated with reduced expression of Sp1 and E2F1. SiRNA-mediated knockdown and ectopic expression of DNMT1 corroborated DNMT1's role in the modulation of gene expression by CG-5. Pyrosequencing revealed differential effects of CG-5 versus 5-aza-deoxycytidine on promoter methylation in these genes. CONCLUSIONS: These findings reveal a previously uncharacterized epigenetic effect of ERMAs on DNA methylation-silenced tumor suppressor genes, which may foster novel strategies for prostate cancer therapy.
BACKGROUND: Targeting tumor metabolism by energy restriction-mimetic agents (ERMAs) has emerged as a strategy for cancer therapy/prevention. Evidence suggests a mechanistic link between ERMA-mediated antitumor effects and epigenetic gene regulation. METHODS: Microarray analysis showed that a novel thiazolidinedione-derived ERMA, CG-12, and glucose deprivation could suppress DNA methyltransferase (DNMT)1 expression and reactivate DNA methylation-silenced tumor suppressor genes in LNCaPprostate cancer cells. Thus, we investigated the effects of a potent CG-12 derivative, CG-5, vis-à-vis 2-deoxyglucose, glucose deprivation and/or 5-aza-deoxycytidine, on DNMT isoform expression (Western blotting, RT-PCR), DNMT1 transcriptional activation (luciferase reporter assay), and expression of genes frequently hypermethylated in prostate cancer (quantitative real-time PCR). Promoter methylation was assessed by pyrosequencing analysis. SiRNA-mediated knockdown and ectopic expression of DNMT1 were used to validate DNMT1 as a target of CG-5. RESULTS:CG-5 and glucose deprivation upregulated the expression of DNA methylation-silenced tumor suppressor genes, including GADD45a, GADD45b, IGFBP3, LAMB3, BASP1, GPX3, and GSTP1, but also downregulated methylated tumor/invasion-promoting genes, including CD44, S100A4, and TACSTD2. In contrast, 5-aza-deoxycytidine induced global reactivation of these genes. CG-5 mediated these epigenetic effects by transcriptional repression of DNMT1, which was associated with reduced expression of Sp1 and E2F1. SiRNA-mediated knockdown and ectopic expression of DNMT1 corroborated DNMT1's role in the modulation of gene expression by CG-5. Pyrosequencing revealed differential effects of CG-5 versus 5-aza-deoxycytidine on promoter methylation in these genes. CONCLUSIONS: These findings reveal a previously uncharacterized epigenetic effect of ERMAs on DNA methylation-silenced tumor suppressor genes, which may foster novel strategies for prostate cancer therapy.
Authors: R C Osthus; H Shim; S Kim; Q Li; R Reddy; M Mukherjee; Y Xu; D Wonsey; L A Lee; C V Dang Journal: J Biol Chem Date: 2000-07-21 Impact factor: 5.157
Authors: Yongxiang Fang; Andrew Brass; David C Hoyle; Andrew Hayes; Abdulla Bashein; Stephen G Oliver; David Waddington; Magnus Rattray Journal: Nucleic Acids Res Date: 2003-08-15 Impact factor: 16.971
Authors: Rebecca L Elstrom; Daniel E Bauer; Monica Buzzai; Robyn Karnauskas; Marian H Harris; David R Plas; Hongming Zhuang; Ryan M Cinalli; Abass Alavi; Charles M Rudin; Craig B Thompson Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: P Cairns; M Esteller; J G Herman; M Schoenberg; C Jeronimo; M Sanchez-Cespedes; N H Chow; M Grasso; L Wu; W B Westra; D Sidransky Journal: Clin Cancer Res Date: 2001-09 Impact factor: 12.531
Authors: Ubaradka G Sathyanarayana; Asha Padar; Makoto Suzuki; Riichiroh Maruyama; Hisayuki Shigematsu; Jer-Tsong Hsieh; Eugene P Frenkel; Adi F Gazdar Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Lisa D Berman-Booty; Po-Chen Chu; Jennifer M Thomas-Ahner; Brad Bolon; Dasheng Wang; Tiffany Yang; Steven K Clinton; Samuel K Kulp; Ching-Shih Chen Journal: Cancer Prev Res (Phila) Date: 2012-12-28
Authors: Bernardo J Krause; Paula M Costello; Ernesto Muñoz-Urrutia; Karen A Lillycrop; Mark A Hanson; Paola Casanello Journal: Epigenetics Date: 2013-07-18 Impact factor: 4.528
Authors: M D Sanchez-Niño; B Fernandez-Fernandez; M V Perez-Gomez; J Poveda; A B Sanz; P Cannata-Ortiz; M Ruiz-Ortega; J Egido; R Selgas; A Ortiz Journal: Cell Death Dis Date: 2015-02-12 Impact factor: 8.469
Authors: Kurosh Ameri; Arman Jahangiri; Anthony M Rajah; Kathryn V Tormos; Ravi Nagarajan; Melike Pekmezci; Vien Nguyen; Matthew L Wheeler; Michael P Murphy; Timothy A Sanders; Stefanie S Jeffrey; Yerem Yeghiazarians; Paolo F Rinaudo; Joseph F Costello; Manish K Aghi; Emin Maltepe Journal: Cell Rep Date: 2015-02-13 Impact factor: 9.423